邹丽宜,女,1975年10月生,广东惠州人,1998年至今工作于学院药理教研室,目前担任药理教研室副主任,广东省抗炎免疫学会常务委员。在动物药效学实验等方面有着良好的经验和实践,主要研究领域有药物抗骨质疏松和脂肪肝肝硬化的药物防护作用研究,目前已毕业的研究生有4名,在读研究生2名。近五年科研论文主要有:
(1)Wu K#,Gong Z#, Zou L#, Ye H, Wang C, Liu Y, Liang Y, Li Y, Ren J, Cui L*, Liu Y*.Sargassum integerrimum inhibits oestrogen deficiency and hyperlipidaemia-induced bone loss by upregulating nuclear factor (erythroid-derived 2)-like 2 in female rats.J Orthop Translat. 2019;19:106-117.
(2)Bei J#, Zhang X#, Wu J, Hu Z, Xu B, Lin S, Cui L, Wu T, Zou L*.Ginsenoside Rb1 does not halt osteoporotic bone loss in ovariectomized rats.PLoS One. 2018;13(9):e0202885.
(3)Liu Y#,Wang WM#,Zou LY#,Li L,Feng L,Pan MZ,Lv MY,Cao Y,Wang H,Kung HF,Pang JX,Fu WM,Zhang JF.Ubiquitin specific peptidase 5 mediates Histidine-rich protein Hpn induced cell apoptosis in hepatocellular carcinoma through P14-P53 signaling.Proteomics.2017 Jun;17(12). doi: 10.1002/pmic.201600350.
(4)Zou L#,Chen S#,Li L*,Wu T*.The protective effect of hyperoside on carbon tetrachloride-induced chronic liver fibrosis in mice via upregulation of Nrf2.Exp Toxicol Pathol.2017;69(7):451-460.
(5)Zhong Y#, Zou L#, Wang Z#, Pan Y, Dai Z, Liu X, Cui L, Zuo C*.Lrrc75b is a novel negative regulator of C2C12 myogenic differentiation.Int J Mol Med. 2016;38(5):1411-1418.
主要课题有:1.广东省科学技术厅,广东省自然科学基金面上项目,2017A030313641,长链非编码RNA 1700018A04Rik调控成骨细胞分化的作用及其机制研究,2017-05至2020-04,10万元,在研,参加
2.广东润和生物有限公司,横向校企合作项目,20141203,辅酶Q10抗骨质疏松症作用研究,2015-01至2017-12,30万,已结题,主持